C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q3 EPS of ($0.44), $0.03 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $11.23 million versus the consensus estimate of $6.13 million.

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.